BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 18, 2003
View Archived Issues
LY-510929 characterized in animal models as a treatment for type 2 diabetes and dyslipidemia
Read More
Preclinical activity of LM-4156, a balanced activator of PPARalpha and PPARgamma
Read More
11-Beta-HSD1 inhibitors presented by Biovitrum researchers
Read More
Dompe patents novel inhibitors of IL-8 and GROalpha-induced chemotaxis
Read More
New aP2 or dual aP2/k-FABP inhibitors and their use disclosed by BMS scientists
Read More
Novel factor Xa inhibitors in early development at GSK
Read More
Bayer claims the preparation and use of synthetic andrimide and moiramide B analogues
Read More
Neurogen patents covers new GABA-A receptor ligands
Read More
ORL1 receptor agonists and their use as antitussives, analgesics, anxiolytics, etc.
Read More
Preclinical data on ISIS-113715, a PTP1B antisense oligonucleotide for the treatment of diabetes
Read More
OSI recovers North American rights to market Gelclair for oncology
Read More
Extended-release alfuzosin approved for BPH
Read More
New phase II study evaluates Dacogen in combination with Gleevec for CML
Read More
Inhibition of p38 MAP kinase effective for prevention and treatment of diabetes in NOD mice
Read More
Xyotax granted fast track status for advanced NSCLC
Read More
Zavesca approved in Israel for Gaucher's disease
Read More
Adventrx chosen as new corporate identity for Biokeys
Read More
Bile acid sequestrant from BTG, ready for phase III trials, available for licensing
Read More
Vaxim discovers SARS antigenic peptide
Read More
Health-related quality-of-life results from phase III Riquent trial
Read More
Cardiovascular agent offered for licensing by Biorex
Read More
EN-101 enters extension study for myasthenia gravis
Read More
Clinical hold on Enzo Biochem's HIV gene therapy trials lifted
Read More
NS-2330 enters further phase II study in Parkinson's disease
Read More
Trisenox NDA submitted in Japan
Read More
Pipeline update at Celltech Group
Read More
Preclinical antitumor activity of AP-23573 characterized at ASCO meeting
Read More